FDA Signals Stricter, More Predictable Rare Disease Drug Review Framework
The U.S. Food and Drug Administration’s new leadership is moving to reshape how rare disease therapies are evaluated, with an emphasis on consistency, predictability and a more structured approval pathway. The initiative could materially affect drug developers, investors and patients by narrowing the discretion that has long defined this corner of the regulatory process.
